← Back to headlines
Palisade Bio Reports Q1 2026 Results with Rising R&D Expenses
Palisade Bio (PALI) released its first-quarter 2026 results, noting an increase in research and development expenses to $6.4 million.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
